newsfilter
← Latest News
GlobeNewswire·

Calyxt Announces Pricing of Offering Of Common Stock and Warrants and Updates Business and Risk Factor Disclosure

NEW YORK, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, and Calyxt, Inc. ("Calyxt"), a majority-owned (61.8%